Clinical trials: Patients With Tumor
Multiple Myeloma, Lymphoma, Non-Hodgkin
AMD3100 (Plerixafor) Given to NHL and MM Patients to Increase the Number of PBSCs When Given a Mobilizing Regimen of G-CSF
This study evaluates the safety and efficacy of plerixafor given in addition to granulocyte-colony stimulating factor (G-CSF) for collection of peripheral blood stem cells (PBSCs) for autologous transplantation in patients with…
- Trial name
- NCT00396266
- Testing
- G-CSF Plus Plerixafor
- Where
- 2 sites in Canada
- Volunteers
- 22 people
- Sponsor
- Genzyme, a Sanofi Company
Advanced Solid Tumor, Hematological Malignancy
An Open-Label, Multicenter, Phase I Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of YY201 in Patients With Advanced Solid Tumors and Hematological Malignancies
This is a multicenter, open-label, phase I clinical study of YY201 in the patients with relapsed/refractory lymphomas and relapsed/refractory large granular lymphocytic leukemia who failed or cannot tolerate standard treatment.
- Trial name
- NCT06225856
- Testing
- YY201
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Shanghai Yuyao Biotech Co., Ltd.
Solid Tumors
Dose Escalation Study of the Safety and Pharmacokinetics of ME-344 Single Agent for Refractory Solid Tumors
The purpose of this study is to determine the tolerability of ME-344, find the maximum tolerated dose, and the safety profile in patients with refractory solid tumors.
- Trial name
- ME-344-001 (NCT01544322)
- Testing
- ME-344
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- MEI Pharma, Inc.
Neoplasms
A Trial of Thalidomide, Celecoxib, Etoposide and Cyclophosphamide in Patients With Relapsed or Progressive Cancer
This study will use a combination of four oral drugs (thalidomide, cyclophosphamide, etoposide and celecoxib) to treat patients with relapsed or progressive cancer.
- Trial name
- NCT00165451
- Testing
- Thalidomide, Celecoxib, Etoposide
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Dana-Farber Cancer Institute
Renal Cell Carcinoma
DC Vaccine Combined With CIK Cells in Patients With Renal Cell Carcinoma
The aim of this Phase I/II study is to evaluate the safety and efficacy of dendritic cells (DC) vaccine combined with cytokine-induced killer (CIK) cells in patients with renal cell carcinoma.
- Trial name
- NCT01924156
- Testing
- adenovirus-transfected DC + CIK
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Affiliated Hospital to Academy of Military Medical Sciences
Hormone Refractory Prostate Cancer
Study of Patupilone in Prostate Cancer Patients Who Progress After Hormone Therapy and Docetaxel Chemotherapy
The purpose of this study is to determine the efficacy of patupilone chemotherapy and to find out what effects (good and bad) the drug Patupilone has on patients with prostate cancer that has progressed following hormone…
- Trial name
- NCT00407251
- Testing
- Patupilone
- Where
- 5 sites in Canada
- Volunteers
- 73 people
- Sponsor
- British Columbia Cancer Agency
Recurrent Bladder Cancer, Transitional Cell Carcinoma of the Bladder
Sunitinib Malate in Treating Patients With Recurrent Transitional Cell Bladder Cancer
RATIONALE: Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor.
- Trial name
- NCT01118351
- Testing
- sunitinib malate, immunohistochemistry staining method, TdT-mediated dUTP nick end labeling assay
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Case Comprehensive Cancer Center
Pancreatic Cancer, Cancer of Pancreas
BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer
In light of the central role of extracellular signal-regulated kinases (ERK) in pancreatic cancer, the investigators propose a phase I study to evaluate the ERK inhibitor BVD-523 at the recommended phase 2 dose in combination…
- Conditions
- Pancreatic Cancer, Cancer of Pancreas, Cancer of the Pancreas, Pancreas Cancer
- Trial name
- NCT02608229
- Testing
- BVD-523, Nab-paclitaxel, Gemcitabine
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Washington University School of Medicine
Melanoma
A Study of ONCOS-102 in Combination With Other Novel Immune-therapies in Advanced Treatment-resistant Melanoma Patients
A Phase 2 study investigating the efficacy and safety of ONCOS-102 alone or in combination with balstilimab (a programmed death receptor-1 [PD-1] inhibitor).
- Trial name
- NCT05561491
- Testing
- ONCOS-102, Balstilimab
- Sponsor
- Targovax Oy
Lymphoma
S0313 Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Radiation Therapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin, vincristine, and prednisone, use different ways to stop cancer cells from dividing so they stop growing or die.
- Trial name
- NCT00070018
- Testing
- rituximab, Cyclophosphamide, doxorubicin hydrochloride
- Where
- 48 sites in United States
- Volunteers
- 46 people
- Sponsor
- SWOG Cancer Research Network
Breast Cancer, Breast Carcinoma
Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer
The goal of this clinical research study is to learn if the study drug, alisertib (MLN8237), in combination with chemotherapy (paclitaxel), can shrink or slow tumor growth in women with hormone receptor (HR)-positive, human…
- Conditions
- Breast Cancer, Breast Carcinoma, Breast Tumors, Malignant Neoplasm of Breast
- Trial name
- NCT02187991
- Testing
- Paclitaxel, Alisertib
- Where
- United States
- Volunteers
- 169 people
- Sponsor
- US Oncology Research
Cutaneous T-cell Lymphoma Stage I, Cutaneous T-cell Lymphoma Stage II
Vorinostat in Patients With Primary Cutaneous T-Cell Lymphoma
This phase II trial studies the side effects and how well vorinostat works in treating patients with primary cutaneous T-cell lymphoma.
- Conditions
- Cutaneous T-cell Lymphoma Stage I, Cutaneous T-cell Lymphoma Stage II, Cutaneous T-cell Lymphoma Stage III, Cutaneous T-cell Lymphoma Stage IV
- Trial name
- NCT00958074
- Testing
- vorinostat, flow cytometry, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Washington
Frailty, Oncology
Approaches and Metrics in Fraily Patients During COVID-19 Era
The COVID-19 pandemic started in December 2019 in Wuhan, the Chinese province of Hubei. Compared to the period of the first epidemic wave (March to May 2020), in the period of the second epidemic wave (October 2020 to July 2021)…
- Conditions
- Frailty, Oncology, Immune Deficiency
- Trial name
- COMETA (NCT05792891)
- Testing
- Collecting biological material from frail patients, with or without COVID-19
- Where
- 2 sites in Italy
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Regina Elena Cancer Institute
Liver Cancer, Adult, MASH - Metabolic Dysfunction-Associated Steatohepatitis
Time-restricted Eating and Healthy Eating in Patients With Metabolic Liver Disease or Cancer
This is a feasibility study that will collect data to assess the potential effect of nutritional intervention. This prospective single-site trial will enroll adult patients with liver diseases such as metabolic-dysfunction…
- Conditions
- Liver Cancer, Adult, MASH - Metabolic Dysfunction-Associated Steatohepatitis, Obesity and Overweight
- Trial name
- TRE+HE (NCT06824974)
- Testing
- Time-restricted eating plus healthy diet
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of California, San Diego
Prostate Cancer, Prostate Adenocarcinoma
Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence
This study evaluates the value of Gallium-68 labeled PSMA (68Ga-PSMA) for PET/CT imaging of prostate cancer recurrence. 68Ga-PSMA is a radioactive molecule, which binds to prostate cancer cells.
- Conditions
- Prostate Cancer, Prostate Adenocarcinoma, Prostate Cancer Metastatic, Prostate Cancer Recurrent
- Trial name
- NCT03396874
- Testing
- 68Ga-PSMA
- Where
- United States
- Volunteers
- 1,435 people
- Sponsor
- University of Michigan
Inherited Hematological Diseases, Rare Diseases
Longitudinal Studies of Patient With FPDMM
Background: Genes tell the body and its cells how to work. Familial platelet disease (FPD) or FPD with associated malignancies (FPDMM) is caused by a variant in the gene RUNX1.
- Conditions
- Inherited Hematological Diseases, Rare Diseases, FPDMM
- Trial name
- NCT03854318
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- National Human Genome Research Institute (NHGRI)
Hepatocellular Carcinoma
Continued Administration of G-202 for One Patient With Advanced Hepatocellular Carcinoma
Patient with advanced liver cancer (cancer that has spread to other parts of the body) continues to receive the study drug (G-202) even though patient no longer meets the criteria to be a part of the main treatment study.
- Trial name
- NCT02082691
- Testing
- G-202
- Sponsor
- Devalingam Mahalingam
Early Stage Breast Carcinoma
EXamining PErsonalised Radiation Therapy for Low-risk Early Breast Cancer
This is a randomised, phase III, non-inferiority trial evaluating radiation therapy versus observation following breast conserving surgery and planned endocrine therapy in patients with stage I breast cancer of luminal A subtype…
- Trial name
- EXPERT (NCT02889874)
- Testing
- Omission of radiation therapy
- Where
- 68 sites in Argentina, Australia and 7 more
- Volunteers
- 1,167 people
- Sponsor
- Breast Cancer Trials, Australia and New Zealand
Colorectal Cancer, Liver Metastases
Adjuvant Systemic Chemotherapy With or Without HAI-FUDR in Patients With Resected CRLM
HARVEST is an investigator-initiated prospective randomized controlled study comparing adjuvant intravenous systemic chemotherapy with or without HAI- floxuridine (FUDR) in CRC patients post-liver metastasectomy.
- Conditions
- Colorectal Cancer, Liver Metastases, HAI
- Trial name
- NCT03500874
- Testing
- FUDR, Oxaliplatin, Leucovorin
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Sun Yat-sen University
Acromegaly Due to Pituitary Adenoma, Ketogenic Diet
KETOgenic Diet Therapy in Patients With ACROmegaly
Acromegaly is caused by a tumour located at the base of the brain in the pituitary gland that produces too much growth hormone (GH).
- Conditions
- Acromegaly Due to Pituitary Adenoma, Ketogenic Diet, Mediterranean Diet
- Trial name
- KETOACRO (NCT06949891)
- Testing
- Ketogenic diet, Mediterranean diet
- Where
- Netherlands
- Volunteers
- 60 people
- Sponsor
- Erasmus Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.